Ⅳ期原发性肺癌中国治疗指南(2024版)  

China clinical practice guideline for stageⅣprimary lung cancer(2024 edition)

作　　者：中国医疗保健国际交流促进会肿瘤内科学分会 中国医师协会肿瘤医师分会 石远凯 Medical Oncology Branch of China International Exchange and Promotive Association for Medical and Health Care;Chinese Association for Clinical Oncologists;Shi Yuankai(不详;Department of Medical Oncology,Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100021,China)

机构地区：[1]不详 [2]国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院内科抗肿瘤分子靶向药物临床研究北京市重点实验室,北京100021

出　　处：《中华肿瘤杂志》2024年第7期595-636,共42页Chinese Journal of Oncology

基　　金：重大新药创制科技重大专项(2017ZX09304015)。

摘　　要：原发性肺癌(以下简称肺癌)是中国发病率和死亡率最高的恶性肿瘤,2022年中国肺癌新发病例约106.06万例,死亡约73.33万例。由于缺乏有效的早期发现手段,大部分肺癌患者就诊时已是Ⅳ期。以全身治疗为主的多学科综合治疗是Ⅳ期肺癌患者的治疗原则,化疗是Ⅳ期肺癌治疗的基石,但疗效不佳。近年来,随着分子靶向治疗、免疫治疗的飞速发展,Ⅳ期肺癌的治疗理念在不断发生变化,患者的治疗效果得到了很大改善。为了及时反映国内外Ⅳ期肺癌治疗的新进展,进一步提高中国Ⅳ期肺癌的规范化诊疗水平,中国医疗保健国际交流促进会肿瘤内科学分会和中国医师协会肿瘤医师分会组织专家编写了《Ⅳ期原发性肺癌中国治疗指南(2024版)》。《Ⅳ期原发性肺癌中国治疗指南(2024版)》在《Ⅳ期原发性肺癌中国治疗指南(2021年版)》和《Ⅳ期原发性肺癌中国治疗指南(2023年版)》的基础上对流行病学数据、TNM分期、2024年6月30日之前获得中国国家药品监督管理局批准的新药、治疗方案和新适应证等方面进行了系统、全面的更新,增加了治疗药物推荐级别和Ⅳ期肺癌治疗流程图等。指南涵盖了Ⅳ期肺癌诊治过程中常见的临床问题和相应指导建议,旨在指导Ⅳ期肺癌临床实践,全面提高中国Ⅳ期肺癌规范化诊治水平,以期延长Ⅳ期肺癌患者的生存时间、改善生活质量。Primary lung cancer(abbreviated as lung cancer)stands as the most prevalent malignant disease and the leading cause of cancer-related death in China,with an estimated 106.06×104 incident cases and 73.33×104 deaths in 2022.Due to the absence of effective early screening methods,most patients with lung cancer in China are in stageⅣwhen diagnosed.Multi-disciplinary treatment based on systemic therapy is the treatment principle for patients with stageⅣlung cancer.Chemotherapy remains the cornerstone,but its effectiveness is still unsatisfactory.In recent years,with the rapid development of molecular targeted therapy and immunotherapy,the treatment concept for stageⅣlung cancer has been continually evolving,leading to significant improvements in patient treatment outcomes.To ensure timely updates on the global progress in the treatment of stageⅣlung cancer and further improve the level of standardized diagnosis and treatment of stageⅣlung cancer in China,Medical Oncology Branch of China International Exchange and Promotive Association for Medical and Health Care and Chinese Association for Clinical Oncologists organized experts to compile"China clinical practice guideline for stageⅣprimary lung cancer(2024 edition)".This guideline systematically and comprehensively updates epidemiological data,TNM staging,new drugs,treatment regimens,and new indications approved by China National Medical Products Administration before June 30,2024,etc.Based on the"Clinical practice guideline for stageⅣprimary lung cancer in China(2021 version)"and the"Clinical practice guideline for stageⅣlung cancer in China(2023 edition)."This guideline incorporates recommendation levels for therapeutic drugs and treatment flowcharts for stageⅣlung cancer.The guideline covers common clinical issues and corresponding guidance in the diagnosis and treatment process of stageⅣlung cancer.The guideline aims to guide the clinical practice of stageⅣlung cancer,comprehensively improve the standardized diagnosis and treatment level in

关 键 词：肺肿瘤 诊断 治疗 指南 

分 类 号：R734.2[医药卫生—肿瘤]